Cardiovascular risk reduction throughout GLP-1 receptor agonist and SGLT2 inhibitor modulation of epicardial fat

G. Iacobellis, M. G. Baroni

Research output: Contribution to journalReview articlepeer-review

Abstract

Epicardial adipose tissue is a novel cardiovascular risk factor. It plays a role in the progression of coronary artery disease, heart failure and atrial fibrillation. Given its rapid metabolism, clinical measurability, and modifiability, epicardial fat works well as therapeutic target of drugs modulating the adipose tissue. Epicardial fat responds to glucagon-like peptide 1 receptor agonists (GLP1A) and sodium glucose co-transporter 2 inhibitors (SGLT2i). GLP-1A and SGLT2i provide weight loss and cardiovascular protective effects beyond diabetes control, as recently demonstrated. The potential of modulating the epicardial fat morphology and genetic profile with targeted pharmacological agents can open new avenues in the pharmacotherapy of diabetes and obesity, with particular focus on cardiovascular risk reduction.

Original languageEnglish (US)
JournalJournal of endocrinological investigation
DOIs
StateAccepted/In press - 2021
Externally publishedYes

Keywords

  • Diabetes
  • Epicardial adipose tissue
  • Epicardial fat
  • Glucagon like peptide 1 receptor agonists
  • Heart failure
  • Obesity
  • Sodium glucose co-transporter 2 inhibitors

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint

Dive into the research topics of 'Cardiovascular risk reduction throughout GLP-1 receptor agonist and SGLT2 inhibitor modulation of epicardial fat'. Together they form a unique fingerprint.

Cite this